Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, received CDSCO approval this week.

Tandem Diabetes Care, Inc. TNDM announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s DXCM G7 and G6 Continuous Glucose ...

insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. Receive News & Ratings ...

The growing prevalence of diabetes across the globe is driving demand for diabetes medications. Contributing factors such as sedentary lifestyles, increasing obesity rates, and an aging population are ...